CINECA IRIS Institutional Research Information System

FERRARO, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.467
AS - Asia 2.084
EU - Europa 1.610
SA - Sud America 340
AF - Africa 184
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 7
Totale 7.716
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.390
SG - Singapore 684
IT - Italia 472
CN - Cina 436
HK - Hong Kong 280
SE - Svezia 266
BR - Brasile 265
VN - Vietnam 208
GB - Regno Unito 170
DE - Germania 168
IN - India 151
FR - Francia 118
FI - Finlandia 88
JP - Giappone 82
CI - Costa d'Avorio 79
BG - Bulgaria 78
NL - Olanda 52
TR - Turchia 51
RU - Federazione Russa 41
CA - Canada 39
SN - Senegal 37
ID - Indonesia 28
PL - Polonia 28
AR - Argentina 24
AU - Australia 23
KR - Corea 23
NG - Nigeria 23
IQ - Iraq 20
AT - Austria 19
ES - Italia 19
MX - Messico 19
BD - Bangladesh 18
EC - Ecuador 15
SA - Arabia Saudita 14
PT - Portogallo 13
ZA - Sudafrica 12
IR - Iran 11
UZ - Uzbekistan 11
LT - Lituania 10
CZ - Repubblica Ceca 9
UA - Ucraina 9
VE - Venezuela 9
EG - Egitto 8
IE - Irlanda 8
MA - Marocco 8
PK - Pakistan 8
CO - Colombia 7
JO - Giordania 7
PE - Perù 7
AE - Emirati Arabi Uniti 6
BE - Belgio 6
CL - Cile 6
PH - Filippine 6
RO - Romania 6
GR - Grecia 5
JM - Giamaica 5
KZ - Kazakistan 5
PY - Paraguay 5
XK - ???statistics.table.value.countryCode.XK??? 5
AZ - Azerbaigian 4
CR - Costa Rica 4
DZ - Algeria 4
NP - Nepal 4
CH - Svizzera 3
DK - Danimarca 3
HR - Croazia 3
IL - Israele 3
KE - Kenya 3
KG - Kirghizistan 3
LV - Lettonia 3
MY - Malesia 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AL - Albania 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
EU - Europa 2
GH - Ghana 2
GT - Guatemala 2
MK - Macedonia 2
PS - Palestinian Territory 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
EE - Estonia 1
GE - Georgia 1
HN - Honduras 1
IS - Islanda 1
JE - Jersey 1
LB - Libano 1
LK - Sri Lanka 1
Totale 7.707
Salva come PNG Salva come JPEG
Città #
Ashburn 441
Singapore 385
San Jose 276
Hong Kong 275
Santa Clara 246
Dallas 213
Chandler 149
Shanghai 144
Fairfield 92
Boardman 82
New York 82
Florence 81
Abidjan 79
Sofia 78
Los Angeles 75
London 74
Beijing 68
Munich 67
Ho Chi Minh City 66
Tokyo 62
Hanoi 52
Princeton 50
Helsinki 47
Pisa 42
Houston 41
Lauterbourg 39
Serra 39
Dakar 37
Wilmington 36
Istanbul 35
Lawrence 34
Milan 33
Turku 31
Woodbridge 30
Mumbai 29
Kent 28
Medford 28
Frankfurt am Main 25
Rome 25
Seattle 24
Lagos 23
Cambridge 21
Council Bluffs 21
Redwood City 21
Hyderabad 20
Rio de Janeiro 20
Massa 19
Ann Arbor 18
Buffalo 18
Hefei 18
San Francisco 18
Jakarta 17
Redondo Beach 17
Warsaw 17
São Paulo 16
Bremen 15
Da Nang 15
Chicago 14
Denver 14
San Diego 14
Brooklyn 13
Chennai 13
Phoenix 13
Amsterdam 12
Atlanta 12
Ogden 12
Washington 12
Fuzhou 11
Dong Ket 10
Mexico City 10
Tashkent 10
Bengaluru 9
Düsseldorf 9
Johannesburg 9
Montreal 9
Nuremberg 9
Orem 9
Belo Horizonte 8
Curitiba 8
Livorno 8
Manchester 8
Marseille 8
Paris 8
Seoul 8
Amman 7
Baghdad 7
Haiphong 7
Madrid 7
Naples 7
Ottawa 7
Roubaix 7
Turin 7
Vancouver 7
Vienna 7
Birmingham 6
Brasília 6
Brussels 6
Cascina 6
Jeddah 6
Jeju City 6
Totale 4.440
Salva come PNG Salva come JPEG
Nome #
Raynaud’s Phenomenon Associated with Calcitonin Gene-Related Peptide (CGRP) Antagonists: a Disproportionality Analysis on VigiBase 839
The Anti-TNF Drugs and the Risk of Lymphoma, Skin Cancer and Melanoma: A Signal Detection Analysis 203
Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy) 198
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study 178
Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy 175
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy 174
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) 165
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons 159
Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases 159
Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports 158
Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis 155
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs 150
The usefulness of listening social media for pharmacovigilance purposes: a systematic review 149
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline 147
Fatal Fat Overload Syndrome Following Intravenous Lipid Emulsion Administration as Antidote in Suspected Anesthetic Intoxication: A Fatal Medication Error. 146
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy 142
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study) 141
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database 138
Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies 137
Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases 135
Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact 134
Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy 133
Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study 133
Listening Social Media for Pharmacovigilance Objectives: Which Usefulness? 133
Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study 131
Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study 130
Erratum to: Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System (Drug Safety, (2023), 46, 3, (283-295), 10.1007/s40264-022-01269-x) 128
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future 128
Disproportionality Analysis of ‘‘Early-Onset’’ Tardive Dyskinesia Stratified by Time to Onset Using FAERS Database. 127
The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy 127
THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES 127
Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance 125
Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients 122
Evaluation of drug-utilization and healthcare facilities use in patients with ulcerative colitis and treated with biologic therapy using data of an Italian healthcare administrative database: Results from michelangelo study 118
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease 113
Anticoagulant Therapy in Patients with Atrial Fibrillation and Risk of Bleeding: Interim Analysis: Tyrion Study 111
Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments 111
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients 111
Analysis of the Drug Related Emergency Department Admissions in Tuscany: The FARO Project 110
Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: Systematic review and meta-analysis 110
A Model-Based Analysis on Direct Costs of Adverse Drug Events and Related Cost-Savings Achievable by their Prevention in Tuscany, Italy 108
The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance 107
Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy 100
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis 96
Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use 94
Supporting the Spontaneous Reporting by Health Care Professionals of the University Hospital of Pisa, Italy: a Pilot Project from the Unit of Adverse Drug Reactions Monitoring 94
Oral Presentation: Signal of Hypertension Associated with COVID-19 Vaccination: VigiBase (R) Data and Evidence from Real World 89
Communicating Drug Safety 88
Assessment of Healthcare Facilities Associated with JAKi Drugs Used in Rheumatoid Arthritis Patients in Tuscany, Italy: The LEONARDO 86
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence 80
Oral Presentation: Accesses to Emergency Department and Hospitalizations in New Users of Biologic Therapies for Ulcerative Colitis in Tuscany: The MICHELANGELO Study 79
Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option 77
COVID-19 Vaccines and Thromboembolic Events with Thrombocytopenia: Data from Italian Pharmacovigilance Public Database 73
Signals of Possibly Persistent Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Disproportionality Analysis Using the EudraVigilance Database 70
Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data 70
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall 65
Unresolved Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Signal Detection Analysis on Publicly Accessible Eudravigilance Data 59
null 56
Cases of acquired hemophilia A following COVID‐19 vaccines: Cogent safety signal or possible reporting/detection bias? Preliminary evidence from Tuscany, Italy 20
Totale 7.821
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.752
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.752
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202198 0 0 0 0 0 0 0 0 0 0 0 98
2021/2022621 12 16 70 75 89 88 25 32 31 19 44 120
2022/2023818 110 156 57 45 65 68 27 32 179 1 75 3
2023/2024682 17 34 42 16 65 99 85 48 38 37 104 97
2024/20252.210 38 87 102 176 149 263 188 78 224 261 247 397
2025/20263.178 236 186 280 251 292 143 409 112 215 251 754 49
Totale 7.821